London
· Delayed Price · Currency is GBP · Price in USD Equillium Company Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.
The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.
In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area.
Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy.
The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2017 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 44 |
| CEO | Bruce Steel |
Contact Details
Address: 2223 Avenida De La Playa La Jolla, Delaware 92037 United States | |
| Phone | 858 240 1200 |
| Website | equilliumbio.com |
Stock Details
| Ticker Symbol | 0A4D |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bruce Steel | Chief Executive Officer |
| Jason Keyes | Chief Financial Officer |
| Christine Zedelmayer | Chief Operating Officer |
| Michael Moore | Head of Investor Relations |